Logo for Gritstone bio Inc

Gritstone bio Investor Relations Material

Latest events

Logo for Gritstone bio Inc

Status Update

Gritstone bio
Logo for Gritstone bio

Q2 2024

13 Aug, 2024
Logo for Gritstone bio

Status Update

2 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Gritstone bio Inc

Access all reports
Gritstone bio, Inc. is a clinical-stage biotechnology company engaged in developing immunotherapies against multiple cancer types and infectious diseases. It offers, among others, SYSTIMAX, an intravenous immunotherapy for the treatment of patients with acute myeloid leukemia (AML), and other related blood cancers, and SYSTIMAX-ID, an intravenous immunotherapy for the treatment of patients with infectious diseases. Its immunotherapies include fully human monoclonal antibodies that target specific antigens associated with the surfaces of cells that drive malignancies or infection.